Home > Publications database > Treatment and survival of early non-metastatic breast cancer in men: real world data from a population-based registry. > print

001     303658
005     20250820114611.0
024 7 _ |a 10.1007/s00404-025-08139-8
|2 doi
024 7 _ |a pmid:40824530
|2 pmid
024 7 _ |a 0003-9128
|2 ISSN
024 7 _ |a 0170-9925
|2 ISSN
024 7 _ |a 0932-0067
|2 ISSN
024 7 _ |a 1432-0711
|2 ISSN
037 _ _ |a DKFZ-2025-01721
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Jakob, D.
|b 0
245 _ _ |a Treatment and survival of early non-metastatic breast cancer in men: real world data from a population-based registry.
260 _ _ |a Heidelberg
|c 2025
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1755678627_25160
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a epub
520 _ _ |a This study aimed to characterize a cohort of male patients with non-metastatic breast cancer, specifically focusing on tumor characteristics, treatment strategies, and determinants of overall survival.Data for this study were obtained from the Baden-Württemberg Cancer Registry, encompassing male patients diagnosed with breast cancer between 2015 and 2023. A total of 470 patient records were included. We described patient and tumor characteristics using descriptive statistics. Overall survival was analyzed using Kaplan-Meier survival curves and Cox proportional hazards regression models to identify significant determinants.In our cohort of male patients with non-metastatic breast cancer, luminal subtype was the predominant tumor biology, accounting for 90% of cases. HER2-positive tumors were observed in 9% of patients, while triple-negative tumors were rare, with only four cases identified. Regarding tumor staging, 81.7% of patients were diagnosed at T1 or T2 stages. However, a substantial proportion (48.7%) presented with clinically involved lymph nodes, and 27.1% were diagnosed at UICC stage III. The five-year overall survival rate for the cohort was 73.7%. Treatment analysis revealed that 86% of patients underwent surgical intervention. Mastectomy combined with sentinel lymph node dissection was the most frequent surgical procedure, performed in 50.6% of cases. Adjuvant radiotherapy was administered to 72.8% of patients. Cox regression analysis identified age, nodal status, and surgical intervention as significant determinants of overall survival.
536 _ _ |a 319H - Addenda (POF4-319H)
|0 G:(DE-HGF)POF4-319H
|c POF4-319H
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Male breast cancer
|2 Other
650 _ 7 |a Real-world data
|2 Other
650 _ 7 |a Surgery
|2 Other
700 1 _ |a Dannehl, D.
|b 1
700 1 _ |a Endres, H.
|b 2
700 1 _ |a Jansen, L.
|0 P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09
|b 3
|u dkfz
700 1 _ |a Hermann, S.
|0 P:(DE-He78)a8ce1da94e91296e574e4849cfabd230
|b 4
|u dkfz
700 1 _ |a Hartkopf, A. D.
|b 5
700 1 _ |a Huwer, S.
|b 6
700 1 _ |a Jung, L.
|b 7
700 1 _ |a Thijssen, O.
|b 8
700 1 _ |a Juhasz-Böss, I.
|b 9
700 1 _ |a Taran, F. A.
|b 10
773 _ _ |a 10.1007/s00404-025-08139-8
|0 PERI:(DE-600)1458450-5
|p nn
|t Archives of gynecology and obstetrics
|v nn
|y 2025
|x 0003-9128
909 C O |o oai:inrepo02.dkfz.de:303658
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)a8ce1da94e91296e574e4849cfabd230
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-319H
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Addenda
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-11
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-11
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ARCH GYNECOL OBSTET : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-11
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-11
920 1 _ |0 I:(DE-He78)M110-20160331
|k M110
|l M110 Epidemiologisches Krebsregister BW
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)M110-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21